On March 9, 2026, the National Organization for Medicines announced the temporary reopening of its digital submission platform for the declaration of authenticity tapes affixed to pharmaceutical packaging. The update specifically targets Marketing Authorization Holders (MAHs) and local representatives responsible for medicines marketed in Greece.
The submission window is open from 09 March 2026 at 08:00 to 10 March 2026 at 23:59, allowing stakeholders to declare authenticity tapes that were already applied to pharmaceutical packaging but were not reported by the original statutory deadline of 20 February 2026. This initiative forms part of EOF’s enforcement of pharmaceutical serialization and anti-counterfeiting regulations under applicable Greek legislation.
Details of the Update
The reopened platform provides a limited opportunity for double-confirmation of authenticity tape reporting. This measure allows MAHs and local representatives to submit declarations for tapes that were previously omitted from submissions due by the 20 February 2026 deadline.
The declaration window is strictly limited to authenticity tapes that have already been applied to pharmaceutical packaging but were not reported during the initial reporting period. No new applications are covered under this reopening.
EOF emphasizes that prompt and complete compliance is required, noting that continued failure to report authenticity tapes may lead to regulatory enforcement actions or penalties. The update reinforces the regulator’s focus on traceability, product authenticity, and anti-counterfeiting safeguards within the pharmaceutical supply chain in Greece.
Feedback Deadline
The EOF submission platform for declaring previously unreported authenticity tapes will remain open from 09 March 2026 (08:00) until 10 March 2026 (23:59).
Why It Matters
This update reinforces regulatory oversight related to serialization and anti-counterfeiting compliance in the Greek pharmaceutical market. By providing a short reopening period for declarations, EOF supports improved data accuracy, traceability, and supply chain transparency, while maintaining regulatory consistency and minimal operational disruption for affected companies.
Who This Is Relevant For
The announcement is particularly relevant for Marketing Authorization Holders, local pharmaceutical representatives, regulatory affairs teams, quality assurance professionals, and compliance teams responsible for the distribution, reporting, and regulatory oversight of medicines in Greece.
Next Steps
Regulatory teams should review records of authenticity tape applications and cross-check them against previous submissions made before the 20 February 2026 deadline. Any omissions should be identified quickly, and the required declarations must be submitted through the EOF platform within the reopening window from 09 to 10 March 2026 to avoid potential compliance risks.
Organizations operating across multiple regulated markets often face similar short-notice regulatory updates. Platforms such as RegASK help compliance and regulatory teams monitor changes, track obligations, and streamline submissions across jurisdictions.
RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What is the new CDE guidance on influenza vaccine clinical trials?
Portfolio and Technology Meetings (PTMs) are structured virtual meetings organized by the European Medicines Agency to allow large pharmaceutical companies to discuss product portfolio development challenges and emerging technologies with the regulator.
Who can apply for EMA Portfolio and Technology Meetings?
The PTM program is open to large pharmaceutical companies with extensive medicinal product portfolios. Eligible companies must submit an application form to the EMA for review.
When is the deadline to apply for a PTM in 2026?
The application deadline is April 30, 2026. The EMA will communicate application outcomes by the end of May 2026, and approved meetings will take place in the second half of 2026.
How can RegASK help organizations manage updates like this?
RegASK’s agentic AI regulatory intelligence platformhelps pharmaceutical companies monitorglobal regulatory announcements, engagement opportunities, and consultation programs in real time. This enables regulatory teams to identify initiatives such as EMA Portfolio and Technology Meetings, coordinate internal preparation, and maintain compliance readiness across complex global pipelines.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
